Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2021.239 | Retrospective cohort study for early detection of new-onset chronic diseases in recovered COVID-19 patients using population-based datasets | Prof. WONG Grace Lai Hung |
| 2013.550 | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg-Negative, Chronic Hepatitis B | Prof. WONG Grace Lai Hung |
| 2019.399 | Role of cryoglobulin in patients with chronic kidney disease | Dr. WONG Grace Lai Hung |
| 2018.178 | A novel NAFLD-LE model based on liver stiffness measurement and enhanced liver fibrosis (ELF) to predict clinical events in patients with non-alcoholic fatty liver disease |
Dr. WONG Grace Lai Hung 黃麗虹 |
| 2018.554 | A Phase 1b Open-Label, Proof of Concept Study to Evaluate the Safety and Efficacy of Novel Hepatitis B Virus (HBV) Combination Therapies in Chronic Hepatitis B (CHB) Subjects | Prof. WONG Grace Lai Hung |
| 2020.509 | A Phase 2a, Multicenter, Single-Blind, Placebo-Controlled, Multiple Cohort Study Evaluating ABI-H2158-Containing Regimens in Chronic Hepatitis B Infection |
Prof Wong Grace Lai Hung 黃麗虹 |
| 2018.188 | Machine Learning Model to Predict Clinical Events in Patients with History of Peptic Ulcer Bleeding | Dr. WONG Grace Lai Hung |
| 2018.646 | Disease burden of chronic viral hepatitis in Hong Kong – towards eliminating viral hepatitis by year 2030 according to World Health Organization (WHO) targets | Dr. WONG Grace Lai Hung |
| 2018.647 | Gastrointestinal and hepatic adverse events of immune checkpoint inhibitors (ICI) - a territory-wide observational cohort study | Dr. WONG Grace Lai Hung |
| 2018.177 | Secular trend of hepatic events in patients with diabetes mellitus - a retrospective observational cohort study |
Dr. WONG Grace Lai Hung 黃麗虹 |
| 2019.348 | Tenofovir alafenamide (TAF) treatment uptake and impact on ALT normalization in patients with chronic hepatitis B in Hong Kong – real-world cohort study (TAF-RW-HK study) | Dr. WONG Grace Lai Hung |
| 2020.544 | Deep learning of combined clinical data and CT images in patients with chronic viral hepatitis – risk prediction and complication reduction to facilitate eliminating viral hepatitis by year 2030 |
Prof. WONG Grace Lai Hung 黃麗虹 |
| 2020.074 | Secular trend of coronavirus infections - a retrospective observational cohort study |
Dr. WONG Grace Lai Hung 黃麗虹 |
| 2019.260 | AN OBSERVER BLIND, RANDOMIZED STUDY WITH AN OPEN LABEL PART TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SUBCUTANEOUS ADMINISTRATION OF RO7191863 WITH MULTIPLE DOSES AND DIFFERENT REGIMENS IN VIROLOGICALLY SUPPRESSED PATIENTS WITH CHRONIC HEPATITIS B INFECTION |
Prof. WONG Grace Lai Hung 陳力元 |
| 2020.090 | Serum fibrosis scores based on common laboratory parameters to guide screening strategies for early identification of hepatocellular carcinoma in patients with chronic hepatitis B |
Dr. WONG Grace Lai Hung 黃麗虹 |
| 2020.310 | A Phase 2a, Multicenter, Single-Blind, Placebo-Controlled Study Evaluating Treatment Intensification with ABI-H0731 in Subjects with Chronic Hepatitis B Infection on Nucleos(t)ide Reverse Transcriptase Inhibitors | Prof. WONG Grace Lai Hung |
| 2019.690 | Response after End of Treatment with Antivirals in Chronic Hepatitis B | Prof. WONG Grace Lai Hung |
| 2020.459 | Elimination of chronic hepatitis B in Hong Kong – to meet the WHO goals |
Prof. WONG Grace Lai Hung 黃麗虹 |
| 2018.297 | A Phase 2, Randomized, Open-Label, Active-Controlled Study to Evaluate the Safety and Antiviral Activity of GS-9992 Plus Tenofovir Alafenamide (TAF) for 12 Weeks in Chronic Hepatitis B (CHB) Subjects |
Prof. WONG Grace Lai Hung 陳力元教授 |
| 2020.615 | Evaluation of AFP, AFP-L3, PIVKA-II and GALAD Score (Gender, Age, AFP-L3, AFP, DCP/PIVKA-II) for risk assessment of Hepatocellular Carcinoma (HCC) | Prof. WONG Grace Lai Hung |
| 2021.106 | Prospective evaluation of a fast-track treatment pathway for patients with chronic hepatitis B under primary care |
Prof. WONG Grace Lai Hung 黃麗虹 |
| 2022.678 | A Phase 2 Study Evaluating the Efficacy and Safety of VIR-3434 and/or VIR-2218 Containing Regimens in Participants with Chronic Hepatitis B Infection (STRIVE) | Prof. WONG Grace Lai Hung |
| 2023.039 | A Phase 1b Multi-Center, Open-Label, Dose-Escalation, Prime and Boost Vaccination Evaluation of Two Chimpanzee Adenoviral Vectors in Adult Participants With Chronic HBV Infection Who Are Currently Receiving HBV Nucleos(t)ide Reverse Transcriptase Inhibitors | Prof. WONG Grace Lai Hung |
| 2022.653 | A Phase 1/2a, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of BJT-778 in Healthy Volunteers and in Subjects with Chronic Hepatitis B Infection, Including Subjects with Chronic Hepatitis D Infection | Prof. WONG Grace Lai Hung |
| 2021.112 | A Phase 2 Multicenter, Randomized, Open-label Study to Investigate the Safety and Efficacy of BRII-835 (VIR-2218) and BRII-179 (VBI-2601) Combination Therapy for the Treatment of Chronic Hepatitis B Virus (HBV) Infection | Prof. WONG Grace Lai Hung |
| 2021.427 | A Phase 2a, Open-Label Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB) |
Prof. WONG Grace Lai Hung 黃麗虹教授 |
| 2022.601 | Real-World Data to Assess HCV Patients Treated with SOF/VEL without RBV |
Prof Wong Grace Lai Hung 黃麗虹教授 |
| 2021.297 | A Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of Regimens Conatining VIR-2218, VIR-3434, and/or PEG-IFNa in Subjects with Chronic Hepatitis B Virus Infection |
Prof. WONG Grace Lai Hung 黃麗虹 |
| 2023.344 | A Phase 1/2 Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BW-20507 in Healthy Subjects, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Subjects with Chronic HBV Infection and a Long-term Study to Evaluate the Safety, Tolerability, and Efficacy of BW-20507 in Subjects with Chronic HBV Infection | Prof. WONG Grace Lai Hung |
| 2022.676 | A Phase 2 Study Evaluating the Efficacy and Safety of VIR-3434 and/or VIR-2218 Containing Regimens in HBeAg-negative Participants with Low Viral Burden of Chronic Hepatitis B Infection (THRIVE) | Prof. WONG Grace Lai Hung |
| 2023.684 | A phase II clinical study to evaluate the safety, efficacy, and pharmacokinetics of RBD1016 injection in participants with chronic hepatitis B | Prof. WONG Grace Lai Hung |
| 2024.057 | A Long-Term Follow-up Study for Subjects with Chronic Hepatitis B Previously Treated with Imdusiran (AB-729) | Prof. WONG Grace Lai Hung |
| 2023.151 | A phase 2b, open-label study to evaluate the efficacy, safety, tolerability, immunogenicity and treatment regimens of VTP-300 combined with low-dose nivolumab in Chronic Hepatitis B Infection |
Prof. WONG Grace Lai Hung Grace LH Wong |
| 2023.200 | A Phase 1, Double-Blind, Randomized, Placebo-Controlled, First-in-Human Study of Orally Administered ALG-000184 to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single-Ascending Doses (Part 1) and Multiple-Ascending Doses in Healthy Volunteers (Part 2), and Multiple Doses in Subjects with Chronic Hepatitis B (Part 3) |
Prof. WONG Grace Lai Hung Grace LH Wong |
| 2024.115 | Behavior, Aspirations and Treatment needs of people living with hepatitis B | Prof. WONG Grace Lai Hung |
| 2023.268 | A Phase 2 Multicenter, Randomized, Open-label Study to Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and Pegylated Interferon Alpha (PEG-IFNα) Combination Therapy for the Treatment of Chronic Hepatitis B Virus (HBV) Infection | Prof. WONG Grace Lai Hung |
| 2023.265 | A Phase 1a/1b Study to Evaluate the Safety and Tolerability of Repeated Doses of Nonreplicating Arenavirus Vector Therapeutic Vaccines GS-2829 and GS-6779 in Healthy Participants and Participants With Chronic Hepatitis B (CHB) |
Prof. WONG Grace Lai Hung Lai Hung Wong |
| 2023.273 | A PHASE I STUDY TO INVESTIGATE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO7565020 IN HEALTHY PARTICIPANTS AND IN PARTICIPANTS WITH CHRONIC HEPATITIS B VIRUS INFECTION |
Prof. WONG Grace Lai Hung 35053759 |
| 2022.480 | A PHASE II, RANDOMISED, ADAPTIVE, OPEN-LABEL PLATFORM TRIAL TO EVALUATE EFFICACY AND SAFETY OF MULTIPLE COMBINATION THERAPIES IN PARTICIPANTS WITH CHRONIC HEPATITIS B |
Prof. WONG Grace Lai Hung 黃麗虹教授 |
| 2024.058 | A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple Dose Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AB-101, an Oral PD-L1 Inhibitor, in Healthy Subjects and Subjects with Chronic HBV Infection | Prof. WONG Grace Lai Hung |
| 2022.509 | Sodium-glucose co-transporter-2 inhibitor (SGLT2i) to prevent of liver complications in patients with chronic hepatitis B and diabetes mellitus: a double-blind, randomised, placebo-controlled trial |
Prof. WONG Grace Lai Hung 黃麗虹教授 |
| 2022.324 | Chronic kidney disease progression in chronic hepatitis B patients on tenofovir alafenamide (TAF) versus entecavir |
Prof. WONG Grace Lai Hung 黃麗虹 |
| 2021.517 | A Randomized, Open-Label, Multicenter Study Investigating AB-729, Nucleos(t)ide Analogue and Pegylated Interferon Alfa-2a Treatment in Subjects with Chronic Hepatitis B Infection |
Prof. WONG Grace Lai Hung 黃麗虹 |
| 2024.002 | A Phase 2a, Open-Label Multiple Dose Study Evaluating the Safety, Tolerability, and Pharmacodynamics of Imdusiran (AB-729) in Combination with Intermittent Dosing of Durvalumab, a PD-L1 Monoclonal Antibody, in Subjects with Chronic HBV Infection | Prof. WONG Grace Lai Hung |
| 2022.552 | Phase 3 Multicenter, Randomized, Double-Blind, Study to Assess the Efficacy and Safety of Treatment with Bepirovirsen in Nucleos(t)ide Analogue-treated Participants with Chronic Hepatitis B Virus (B-Well 1) |
Prof. WONG Grace Lai Hung 黃麗虹 |
| 2017.421 | Secular trend of deaths - a retrospective observational cohort study |
Dr. WONG Grace Lai Hung 黃麗虹 |
| 2015.089 | Dynamic change of LSM-HCC score and enhanced liver fibrosis (ELF) score to predict hepatocellular carcinoma (HCC) in chronic hepatitis B patients receiving antiviral treatment |
Prof. WONG Grace Lai Hung 黃麗虹 |
| 2016.005 | REAL-C: Real-World Evidence from the Asia Liver Consortium for HCV |
Dr. WONG Grace Lai Hung 黃麗虹 |
| 2016.140 | Dynamic change of liver and spleen stiffness measurement (LSSM) to predict incident varices in cirrhotic patients |
Dr. WONG Grace Lai Hung 黃麗虹 |
| 2015.121 | Secular trend of etiologies of hepatic events - a retrospective observational cohort study |
Dr. WONG Grace Lai Hung 黃麗虹 |
Page 35 of 262.